-
公开(公告)号：US20080027223A1
公开(公告)日：2008-01-31
申请号：US11690580
申请日：2007-03-23
IPC分类号： C07D487/04
CPC分类号： C07D487/04
摘要： The present invention provides crystalline Eszopiclone malate form II, crystalline Eszopiclone form V, processes from preparing the crystalline Eszopiclone malate form II or V, pharmaceutical compositions comprising the crystalline Eszopiclone malate form II or V and methods of treating insomnia comprising administering the crystalline Eszopiclone malate form II or V.
摘要翻译： 本发明提供结晶埃索替普罗苹果酸盐形式II，结晶埃索普洛尔形式V，从制备结晶依佐匹克隆苹果酸盐形式II或V的方法，包含结晶异山梨酸丙酮酸形式II或V的药物组合物和治疗失眠症的方法，包括施用结晶埃索普洛尔苹果酸盐形式 II或V.
-
公开(公告)号：US20070123550A1
公开(公告)日：2007-05-31
申请号：US11506030
申请日：2006-08-16
IPC分类号： A61K31/505 , C07D239/42
CPC分类号： C07D239/42
摘要： Provided is a crystalline rosuvastatin intermediate and processes for preparation thereof.
摘要翻译： 提供了结晶瑞舒伐他汀中间体及其制备方法。
-
公开(公告)号：US20070043243A1
公开(公告)日：2007-02-22
申请号：US11435430
申请日：2006-05-16
申请人： Revital Lifshitz-Liron , Amihai Eisenstadt , Shlomit Wizel , Sharon Avhar-Maydan , Yuriy Raizi , Revital Ramaty
发明人： Revital Lifshitz-Liron , Amihai Eisenstadt , Shlomit Wizel , Sharon Avhar-Maydan , Yuriy Raizi , Revital Ramaty
IPC分类号： C07C211/27
CPC分类号： C07C209/08 , C07B2200/07 , C07C209/16 , C07C209/22 , C07C211/30
摘要： Processes for preparing cinacalcet are provided.
摘要翻译： 提供了制备西那卡塞的方法。
-
公开(公告)号：US20070004804A1
公开(公告)日：2007-01-04
申请号：US11516363
申请日：2006-09-05
申请人： Ronit Yahalomi , Evgeny Shapiro , Ben-Zion Dolitzky , Igal Gozlan , Boaz Gome , Shlomit Wizel
发明人： Ronit Yahalomi , Evgeny Shapiro , Ben-Zion Dolitzky , Igal Gozlan , Boaz Gome , Shlomit Wizel
IPC分类号： A61K31/198 , C07C237/02
CPC分类号： C07C231/24 , C07B2200/13 , C07C233/63 , C07C2601/14
摘要： Provides are crystalline forms of nateglinide, labeled Forms A, C, D, F, G, I, J, K, L, M, N, 0, P, Q, T, U, V, Y, α, β, γ, δ, ε, δ, σ, 2 and Ω, processes for their preparation and processes for preparation of other crystalline forms of nateglinide. Also provided are their pharmaceutical formulations and methods of administration.
摘要翻译： 提供那格列奈的结晶形式，标记为A，C，D，F，G，I，J，K，L，M，N，0，P，Q，T，U，V，Y，α，β， ，δ，ε，δ，σ，2和Omega，其制备方法和制备其他结晶形式的那格列奈的方法。 还提供了它们的药物制剂和给药方法。
-
公开(公告)号：US07144916B2
公开(公告)日：2006-12-05
申请号：US10994142
申请日：2004-11-19
IPC分类号： C07D207/34 , A61K31/40
CPC分类号： C07D207/34 , A61K9/282 , A61K9/5021 , C07D405/06
摘要： The present invention provides novel forms of atorvastatin designated Forms VI, VIII, IX, X, XI and XII and novel processes for their preparation as well as processes for preparing atorvastatin Forms I, II, IV, V and amorphous atorvastatin.
-
公开(公告)号：US20050004206A1
公开(公告)日：2005-01-06
申请号：US10901845
申请日：2004-07-28
IPC分类号： A61K9/28 , A61K9/50 , A61K31/40 , A61K31/401 , A61P3/06 , A61P9/00 , B01D9/02 , C07D207/34 , C07D405/06
CPC分类号： C07D207/34 , A61K9/282 , A61K9/5021 , C07D405/06
摘要： The present invention provides novel forms of atorvastatin designated Forms VI, VIII, IX, X, XI and XII and novel processes for their preparation as well as processes for preparing atorvastatin Forms I, II, IV, V and amorphous atorvastatin.
-
27.发明授权CRYSTAL FORMS III, IV, V, AND NOVEL AMORPHOUS FORM OF CLOPIDOGREL HYDROGENSULFATE, PROCESSES FOR THEIR PREPARATION, PROCESSES FOR THE PREPARATION OF FORM I, COMPOSITIONS CONTAINING THE NEW FORMS AND METHODS OF ADMINISTERING THE NEW FORMS 失效晶状体III，IV，V和新型非晶形态非晶形态，其制备方法，制备形式I的方法，包含新形式的组合物和管理新形式的方法公开(公告)号：US06767913B2
公开(公告)日：2004-07-27
申请号：US10074409
申请日：2002-02-12
申请人： Revital Lifshitz , Eti Kovalevski-Ishai , Shlomit Wizel , Sharon Avhar Maydan , Rami Lidor-Hadas
发明人： Revital Lifshitz , Eti Kovalevski-Ishai , Shlomit Wizel , Sharon Avhar Maydan , Rami Lidor-Hadas
IPC分类号： A61K3144
CPC分类号： C07D495/04
摘要： The present invention provides new crystalline Forms III, IV and V of clopidogrel hydrogensulfate and the amorphous form of clopidogrel hydrogensulfate, as well as their pharmaceutical compositions, and method of treatments with such compositions. The present invention also provides novel processes for preparation of clopidogrel hydrogensulfate Form I, Form III, Form IV, Form V and the amorphous form. The present invention further provides a novel process where the amorphous form is converted to Form I by contacting Form I with an ether.
摘要翻译： 本发明提供氯吡格雷硫酸氢盐和无定形形式的氯吡格雷硫酸氢盐的新结晶形式III，IV和V，以及它们的药物组合物，以及用这种组合物处理的方法。 本发明还提供了制备氯吡格雷硫酸氢盐形式I，形式III，形式IV，形式V和无定形形式的新方法。 本发明还提供了一种新的方法，其中通过使形式I与醚接触将无定形形式转化成晶型I.
-
公开(公告)号：US07868169B2
公开(公告)日：2011-01-11
申请号：US11506030
申请日：2006-08-16
IPC分类号： C07D239/42 , C07D403/12
CPC分类号： C07D239/42
摘要： Provided is a crystalline rosuvastatin intermediate and processes for preparation thereof.
摘要翻译： 提供了结晶瑞舒伐他汀中间体及其制备方法。
-
公开(公告)号：US20090149497A1
公开(公告)日：2009-06-11
申请号：US12207372
申请日：2008-09-09
申请人： Ben-Zion DOLITZKY , Shlomit Wizel , Barnaba Krochmal , Dov Diller , Irwin Gross
发明人： Ben-Zion DOLITZKY , Shlomit Wizel , Barnaba Krochmal , Dov Diller , Irwin Gross
IPC分类号： A61K31/445 , C07D211/34
CPC分类号： C07D211/22
摘要： The present invention provides novel crystal forms of fexofenadine hydrochloride Forms V, VI and VIII through XV and processes for their preparation and preparation of amorphous form and other crystalline forms of fexofenadine hydrochloride. Forms XIV and XV are solvates of ethyl acetate, while Form IX is anhydrous, but can be crystallized as a solvate of MTBE or cyclohexane. The forms are useful for administration to humans and animals to alleviate symptoms caused by histamine. The present invention further provides pharmaceutical compositions of the new crystalline forms.
摘要翻译： 本发明提供盐酸非索非那定形式V，VI和VIII至XV的新型结晶形式及其制备和制备盐酸非索非那定的无定形形式和其它结晶形式的方法。 形式XIV和XV是乙酸乙酯的溶剂化物，而形式IX是无水的，但可以结晶为MTBE或环己烷的溶剂合物。 这些形式可用于给予人类和动物以减轻组胺引起的症状。 本发明还提供了新的结晶形式的药物组合物。
-
公开(公告)号：US07358390B2
公开(公告)日：2008-04-15
申请号：US10623290
申请日：2003-07-18
申请人： Ronit Yahalomi , Evgeny Shapiro , Ben-Zion Dolitzky , Igal Gozlan , Boaz Gome , Shlomit Wizel
发明人： Ronit Yahalomi , Evgeny Shapiro , Ben-Zion Dolitzky , Igal Gozlan , Boaz Gome , Shlomit Wizel
IPC分类号： C07C229/00
CPC分类号： C07C233/63 , A61K31/198 , C07B2200/13 , C07C2601/14
摘要： Provides are crystalline forms of nateglinide, labeled Forms A, C, D, F, G, I, J, K, L, M, N, O, P, Q, T, U, V, Y, α, β, γ, δ, ε, σ, θ and Ω, processes for their preparation and processes for preparation of other crystalline forms of nateglinide. Also provided are their pharmaceutical formulations and methods of administration.
摘要翻译： 提供那格列奈的结晶形式，标记为A，C，D，F，G，I，J，K，L，M，N，O，P，Q，T，U，V，Y，α，β， ，δ，ε，σ，θ和Ω，它们的制备方法和制备那格列奈的其它结晶形式的方法。 还提供了它们的药物制剂和给药方法。
-
-
-
-
-
-
-
-
-
搜索结果
91 条记录 (耗时 0.029 秒)
